Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6545199

Title:Embryonic germ cells, method for making same, and using the cells to produce a chimeric porcine
Inventors:Anderson, Gary B.; Davis, CA, USA
Shim, Hosup; Davis, CA, USA
Summary:Described herein is a method of preparing ungulate embryonic stem-like cells via the culturing of primordial germ cells collected from an ungulate embryo. The invention relates to a process by which primordial germ cells are extracted from the post blastocyst embryos of an ungulate, such that the primordial germ cells are extracted from the gonadal ridges of 25-day porcine embryos or 34-40 day bovine embryos. The primordial germ cells are then described as being cultured over 30 days, resulting in cells which resemble embryonic stem cells in morphology and also in their ability to maintain pluripotency. Claims of the invention include cells which are maintainable for several months in culture and which can be genetically manipulated using homologous recombination technology in order to insert desired genetic material into the genetic compliment of the cell at a desired location. Further described are the means by which such genetically manipulated cells may be inserted into a blastocyst obtained from the same species of animal as that from which the cell was derived in order to produce a chimeric ungulate. Therapeutic applications provided herein include desired pharmaceutical products genetically engineered from such chimeric ungulates, for the treatment of specific diseases.
Abstract:Primordial germ cells are extracted from post blastocyst embryos of an ungulate such as extracting primordial germ cells from the gonadal ridges of 25-day porcine embryos or 34-40 day bovine embryos. The primordial germ cells are cultured in long term culture (over 30 days) resulting in cells which resemble embryonic stem cells in morphology and with respect to maintaining pluripotency. The cells obtained can be maintained for several months in culture and can be genetically manipulated using homologous recombination technology in order to insert desired genetic material into the genetic compliment of the cell at a desired location. The genetically manipulated cell can be inserted into a blastocyst obtained from the same species of animal as the cell was derived in order to produce a chimeric ungulate which ungulate may, via its genetic engineering, produce desired pharmaceutical products.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6545199
Application Number:US2000000627919
Date Filed:28/07/2000
Date Published:08/04/2003
Assignee:The Regents of the University of California, Oakland, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021